Date: 2013-10-10
Type of information: R&D agreement
Compound: novel enteroendocrine mechanisms, pathways and signals regulating key metabolic processes that have disease-modifying potential in diabetic patients
Company: Evotec (Germany) Harvard University (USA - MA)
Therapeutic area: Metabolic diseases
Type agreement: R&D
collaboration
Action mechanism:
Disease: diabetes
Details: * On October 10, 2013, Evotec has announced a second research collaboration, TargetEEM (Enteroendocrine Mechanisms), with the laboratory of Doug Melton, Xander University Professor in the Department of Stem Cell and Regenerative Biology at Harvard University, Harvard Stem Cell Institute Scientific Co-Director and Howard Hughes Medical Institute Investigator. The objective of this collaboration is to identify novel enteroendocrine mechanisms, pathways and signals regulating key metabolic processes that have disease-modifying potential in diabetic patients. Evotec’s first collaboration with the Melton laboratory was focused on beta cell replication.
TargetEEM is comprehensive screening effort by Harvard and Evotec designed to systematically search for novel pathways and targets that have the potential to address key pathophysiological mechanisms involved in insulin resistance and energy handling. The basis of this effort will be disease-relevant animal models as well as unbiased transcriptional and proteomic profiling platforms contributed by both collaboration partners. Harvard and Evotec will collaborate in a highly integrated and fashion and share potential commercial rewards.
Financial terms: Financial details were not disclosed.
Latest news:
